Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001917972 | SCV002170753 | uncertain significance | Pityriasis rubra pilaris; Psoriasis 2 | 2021-08-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with glutamine at codon 892 of the CARD14 protein (p.Glu892Gln). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and glutamine. This variant is present in population databases (rs770592418, ExAC 0.2%). This variant has not been reported in the literature in individuals affected with CARD14-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003303338 | SCV003994659 | uncertain significance | Inborn genetic diseases | 2023-05-18 | criteria provided, single submitter | clinical testing | The c.2674G>C (p.E892Q) alteration is located in exon 19 (coding exon 18) of the CARD14 gene. This alteration results from a G to C substitution at nucleotide position 2674, causing the glutamic acid (E) at amino acid position 892 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |